OncoMatch/Clinical Trials/NCT05947851
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Is NCT05947851 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Rituximab and Nemtabrutinib for leukemia, lymphocytic, chronic, b-cell.
Treatment: Nemtabrutinib · Venetoclax · Rituximab — The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrutinib plus venetoclax is superior to VR with respect to progression-free survival (PFS) per 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria as assessed by blinded independent central review (BICR).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Cancer type
Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic anticancer therapy
Relapsed or refractory to at least 1 prior available therapy
Cannot have received: BCL2 inhibitor
Has received prior B-cell lymphoma 2 inhibitor(s) (BCL2i) within ≤ 12 months before randomization
Cannot have received: radiotherapy
has received prior radiotherapy within 2 weeks of start of study intervention, or radiation related toxicities, requiring corticosteroids
Cannot have received: systemic anticancer therapy
Has received prior systemic anticancer therapy within 5 half-lives or 4 weeks (if prior therapy was a monoclonal antibody) before randomization
Cannot have received: investigational agent
Has received an investigational agent or has used an investigational device within 4 weeks before study intervention administration
Lab requirements
Blood counts
adequate organ function with specimens collected within 7 days before the start of study intervention
Kidney function
adequate organ function with specimens collected within 7 days before the start of study intervention
Liver function
adequate organ function with specimens collected within 7 days before the start of study intervention
Participants with adequate organ function with specimens collected within 7 days before the start of study intervention
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Highlands Oncology Group ( Site 5405) · Springdale, Arkansas
- MemorialCare Health System - Long Beach Medical Center ( Site 5421) · Long Beach, California
- Memorial Hospital West ( Site 5410) · Pembroke Pines, Florida
- Oregon Health and Science University ( Site 5425) · Portland, Oregon
- Medical Oncology Associates, PS ( Site 5406) · Spokane, Washington
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05947851 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior BCL2 inhibitor, radiotherapy, systemic anticancer therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify